Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 688 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health Crisis Preparedness Plan MOST POPULAR Exosomes May Help Tumors Evade Immune System September 7, 2018 One Million Masks Donated! But GreaterGood Will Continue to Help Where... October 5, 2020 Seven Extra Years July 2, 2022 Health inequalities: Why is it harder for some people to eat... June 24, 2022 Load more HOT NEWS Marshall University Study Finds That Walnuts Suppress Breast Cancer Growth And... Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal... EMA Recommends Extension of Indications for Dostarlimab What could DeepMind ‘solving’ the protein folding problem mean for cancer...
